Zomedica Collaborates With Boehringer Ingelheim to Expand Equine PPID Testing on TRUFORMA

Reuters03-18

Zomedica Collaborates With Boehringer Ingelheim to Expand Equine PPID Testing on TRUFORMA

Zomedica entered a collaboration with Boehringer Ingelheim to expand equine endocrine diagnostic testing for pituitary pars intermedia dysfunction (PPID) using the TRUFORMA platform. The arrangement integrates TRUFORMA into Boehringer Ingelheim’s idPPID awareness and testing program, enabling point-of-care testing using Zomedica’s equine endogenous ACTH and equine insulin assays. Zomedica will promote the idPPID program to veterinarians in its TRUFORMA and PulseVet customer networks, while Boehringer Ingelheim will reimburse participating veterinarians for TRUFORMA-based testing and laboratory testing at Cornell University. The program includes no-cost placement of TRUFORMA analyzers in equine practices and reimbursement for diagnostic cartridge kits, with participating veterinarians able to reorder additional assays including Cortisol and Progesterone.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zomedica Corp. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202603180600ACCESSWRNAPR_____1148679) on March 18, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2620231416?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-18 18:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2620231416","market":"us","top_or_hot":-1,"title":"Zomedica Collaborates With Boehringer Ingelheim to Expand Equine PPID Testing on TRUFORMA","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Zomedica Collaborates With Boehringer Ingelheim to Expand Equine PPID Testing on TRUFORMA\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Zomedica entered a collaboration with Boehringer Ingelheim to expand equine endocrine diagnostic testing for pituitary pars intermedia dysfunction (PPID) using the TRUFORMA platform. The arrangement integrates TRUFORMA into Boehringer Ingelheim’s idPPID awareness and testing program, enabling point-of-care testing using Zomedica’s equine endogenous ACTH and equine insulin assays. Zomedica will promote the idPPID program to veterinarians in its TRUFORMA and PulseVet customer networks, while Boehringer Ingelheim will reimburse participating veterinarians for TRUFORMA-based testing and laboratory testing at Cornell University. The program includes no-cost placement of TRUFORMA analyzers in equine practices and reimbursement for diagnostic cartridge kits, with participating veterinarians able to reorder additional assays including Cortisol and Progesterone.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/ZOMDF\">Zomedica Corp.</a> published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202603180600ACCESSWRNAPR_____1148679) on March 18, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Zomedica Collaborates With Boehringer Ingelheim to Expand Equine PPID Testing on TRUFORMA</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nZomedica Collaborates With Boehringer Ingelheim to Expand Equine PPID Testing on TRUFORMA\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-18 18:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Zomedica Collaborates With Boehringer Ingelheim to Expand Equine PPID Testing on TRUFORMA\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Zomedica entered a collaboration with Boehringer Ingelheim to expand equine endocrine diagnostic testing for pituitary pars intermedia dysfunction (PPID) using the TRUFORMA platform. The arrangement integrates TRUFORMA into Boehringer Ingelheim’s idPPID awareness and testing program, enabling point-of-care testing using Zomedica’s equine endogenous ACTH and equine insulin assays. Zomedica will promote the idPPID program to veterinarians in its TRUFORMA and PulseVet customer networks, while Boehringer Ingelheim will reimburse participating veterinarians for TRUFORMA-based testing and laboratory testing at Cornell University. The program includes no-cost placement of TRUFORMA analyzers in equine practices and reimbursement for diagnostic cartridge kits, with participating veterinarians able to reorder additional assays including Cortisol and Progesterone.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/ZOMDF\">Zomedica Corp.</a> published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202603180600ACCESSWRNAPR_____1148679) on March 18, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4082","symbol_name":"医疗保健设备","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nNDL27FXtQ:1","article_id":"2620231416","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2620231416","pubTimestamp":1773828026,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Zomedica entered a collaboration with Boehringer Ingelheim to expand equine endocrine diagnostic testing for pituitary pars intermedia dysfunction  using the TRUFORMA platform. The arrangement integrates TRUFORMA into Boehringer Ingelheim’s idPPID awareness and testing program, enabling point-of-care testing using Zomedica’s equine endogenous ACTH and equine insulin assays. Zomedica will promote the idPPID program to veterinarians in its TRUFORMA and PulseVet customer networks, while Boehringer Ingelheim will reimburse participating veterinarians for TRUFORMA-based testing and laboratory testing at Cornell University. The program includes no-cost placement of TRUFORMA analyzers in equine practices and reimbursement for diagnostic cartridge kits, with participating veterinarians able to reorder additional assays including Cortisol and Progesterone.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4082":"医疗保健设备","ZOMDF":"Zomedica Corp."},"translate_title":"Zomedica与勃林格殷格翰合作扩大TRUFORMA的马PPID测试","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ZOMDF":0.9},"content_text":"Zomedica Collaborates With Boehringer Ingelheim to Expand Equine PPID Testing on TRUFORMA\n    \n\n        Zomedica entered a collaboration with Boehringer Ingelheim to expand equine endocrine diagnostic testing for pituitary pars intermedia dysfunction (PPID) using the TRUFORMA platform. The arrangement integrates TRUFORMA into Boehringer Ingelheim’s idPPID awareness and testing program, enabling point-of-care testing using Zomedica’s equine endogenous ACTH and equine insulin assays. Zomedica will promote the idPPID program to veterinarians in its TRUFORMA and PulseVet customer networks, while Boehringer Ingelheim will reimburse participating veterinarians for TRUFORMA-based testing and laboratory testing at Cornell University. The program includes no-cost placement of TRUFORMA analyzers in equine practices and reimbursement for diagnostic cartridge kits, with participating veterinarians able to reorder additional assays including Cortisol and Progesterone.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zomedica Corp. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202603180600ACCESSWRNAPR_____1148679) on March 18, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.37.0","shortVersion":"4.37.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2620231416","isCrawlerRequest":true}